Navigating 4 Analyst Ratings For Beam Therapeutics
Portfolio Pulse from Benzinga Insights
Beam Therapeutics (NASDAQ:BEAM) has been analyzed by 4 analysts, showing a shift towards a more cautious stance with 3 indifferent ratings in the last 30 days. The average 12-month price target has been adjusted to $35.00, down from $46.67, indicating a 25.01% decrease. Financial indicators reveal a positive revenue trend with an 8.82% growth rate as of September 30, 2023, but a high net margin of -558.88% and an impressive ROE of -12.08%. The company's debt-to-equity ratio stands at 0.22, showcasing a sound financial structure.
February 28, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Beam Therapeutics has seen a cautious shift in analyst sentiment, with a significant decrease in the average price target. Financials show positive revenue growth but concerns in profitability metrics.
The decrease in the average price target by analysts reflects a more cautious outlook on Beam Therapeutics, likely due to the high net margin of -558.88% indicating significant losses relative to revenue. Despite positive revenue growth, the overall financial health as indicated by ROE and ROA suggests challenges in profitability and asset management. The adjustment in analyst sentiment and the significant reduction in price target could lead to short-term negative pressure on BEAM's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100